Clinical and economic burden of community-acquired pneumonia in the Veterans Health Administration, 2011: a retrospective cohort study

Infection

Volumn 43, Issue 6, 2015, Pages 671-680

  McLaughlin, John M ^a,d   Johnson, Maribeth H ^b,c   Kagan, Stephen A ^a   Baer, Stephanie L ^b,c  

^a Pfizer Vaccines   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c AUGUSTA UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Burden of disease; Community acquired pneumonia; Epidemiology; Risk factor; Risk status; Veterans

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BLACK PERSON; CAUCASIAN; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL AND ECONOMIC BURDEN; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMENTIA; DIABETES MELLITUS; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEART DISEASE; HEART FAILURE; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; LENGTH OF STAY; LIVER DISEASE; LOW RISK POPULATION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICARE; MIDDLE AGED; MIDDLE RISK POPULATION; MORTALITY; OUTPATIENT; RETROSPECTIVE STUDY; RISK; THORAX RADIOGRAPHY; VETERAN; ADOLESCENT; COMMUNITY-ACQUIRED INFECTIONS; ECONOMICS; HOSPITALIZATION; PNEUMONIA; SURVIVAL ANALYSIS; UNITED STATES; VERY ELDERLY; VETERANS HEALTH; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PNEUMONIA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UNITED STATES; VETERANS HEALTH; YOUNG ADULT;

EID: 84948102250     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-015-0789-3     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. The Pink Book: Pneumococcal Disease, 12th Edition Second Printing May 2012. Atlanta: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2012.
2. Song JH, Thamlikitkul V, Hsueh PR. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents. 2011;38:108–17.
3. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–9.
4. Niederman MS. How do we optimize outcomes for patients with severe community-acquired pneumonia? Intensive Care Med. 2002;28:1003–5.
5. Niederman MS. Community-acquired pneumonia: the U.S. perspective. Semin Respir Crit Care Med. 2009;30:179–88.
6. Niederman MS, et al. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20:820–37.
7. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122:130–41.
8. Isea-Pena MC, et al. Risk factors and clinical significance of invasive infections caused by levofloxacin-resistant Streptococcus pneumoniae. Infection. 2013;41:935–9.
9. Melzer M, Welch C. 30-day mortality in UK patients with bacteraemic community-acquired pneumonia. Infection. 2013;41:1005–11.
10. Colice GL, et al. Treatment costs of community-acquired pneumonia in an employed population. Chest. 2004;125:2140–5.
11. Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med. 1985;78:45–51.
12. Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin North Am. 2004;18:761–76 (vii).
13. Centers for Disease Control and Prevention, National Center for Health Statistics, 2010 National Hospital Discharge Survey. Atlanta: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010.
14. Welte T. Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. Eur J Clin Microbiol Infect Dis. 2012;31:33–47.
15. Agha Z, et al. Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med. 2000;160:3252–7.
16. Kazis LE, et al. Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study. Arch Intern Med. 1998;158:626–32.
17. American Thoracic Society & Infectious Diseases Society of. America, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
18. Broulette J, et al. The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits. 2013;6:494–503.
19. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997; 46: 1–24.
20. Kyaw MH, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377–86.
21. Weycker D, et al. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28:4955–60.
22. Phibbs CS, et al. Estimating the costs of VA ambulatory care. Med Care Res Rev. 2003;60:54S–73S.
23. Wagner TH, Chen S, Barnett PG. Using average cost methods to estimate encounter-level costs for medical-surgical stays in the VA. Med Care Res Rev. 2003;60:15S–36S.
24. Chi RC, Reiber GE, Neuzil KM. Influenza and pneumococcal vaccination in older veterans: results from the behavioral risk factor surveillance system. J Am Geriatr Soc. 2006;54:217–23.
25. US Food and Drug Administration, FDA expands use of Prevnar 13 vaccine for people ages 50 and older. US Department of Health and Human Services: Silver Spring; 2011.
26. Tomczyk S, et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >/=65 Years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822–5.
27. Bonten MJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–25.
28. Isturiz, R. and C. Webber, Prevention of Adult Pneumococcal Pneumonia With the 13-Valent Pneumococcal Conjugate Vaccine: CAPiTA, the Community-Acquired Pneumonia Immunization Trial in Adults. Human Vaccine Immunotherap. 2015; 11. (in press).
29. Jackson ML, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39:1642–50.
30. Yu H, et al. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc. 2012;60:2137–43.
31. Hynes DM, et al. Veterans’ access to and use of medicare and veterans affairs health care. Med Care. 2007;45:214–23.
32. Petersen LA, et al. Relationship between clinical conditions and use of Veterans Affairs health care among Medicare-enrolled veterans. Health Serv Res. 2010;45:762–91.
33. Liu CF, et al. Use of outpatient care in Veterans Health Administration and Medicare among veterans receiving primary care in community-based and hospital outpatient clinics. Health Serv Res. 2010;45:1268–86.
34. Liu CF, et al. Reliance on Veterans Affairs outpatient care by Medicare-eligible veterans. Med Care. 2011;49:911–7.